Leta Capital

Leta Capital is an early-stage venture firm originally rooted in the post-Soviet tech ecosystem and now investing predominantly out of Western jurisdictions in B2B software companies founded by emigre engineers. Healthcare is not a stated thesis area, and the public portfolio is heavy on horizontal SaaS, devtools, and fintech rather than clinical or regulated health products. For physician founders building a generalist B2B AI tool with optional health applications, Leta could be a fit at Series A, with checks typically in the low single-digit millions and follow-on capacity at later stages. For founders building anything that requires deep regulatory navigation, payer contracting, or clinical validation, Leta is unlikely to be the lead and probably will not be a productive use of fundraising cycles. The team is technical and prefers founders who can defend product architecture in detail, so a pitch built around clinical workflow narrative without a defensible engineering thesis will not land. The most reliable entry path is a warm introduction from a founder in the existing portfolio or from an operator in the broader Russian-speaking technical diaspora; cold inbound through the website form is read but rarely actioned. Founders should arrive with a clean cap table, a credible international expansion narrative, and a product that can demonstrate retention with paying B2B customers before the conversation turns serious. Treat Leta as a horizontal software investor that will look at health-adjacent companies opportunistically rather than a healthcare-dedicated partner.